P. Kent Hawryluk's Insider Trades & SAST Disclosures
P. Kent Hawryluk's most recent trade in MBX Biosciences Inc. was a trade of 243,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern P. Kent Hawryluk.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| MBX Biosciences Inc. | Peter Kent Hawryluk | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 243,000 | 243,000 | - | - | Stock Option (Right to Buy) | |
| MBX Biosciences Inc. | Peter Kent Hawryluk | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 10.69 per share. | 03 Feb 2025 | 50,000 | 448,277 | - | 10.7 | 534,500 | Common Stock |
| MBX Biosciences Inc. | Peter Kent Hawryluk | Director, President & CEO | 16 Sep 2024 | 2,015,681 | 0 | - | - | Series A Convertible Preferred Stock | ||
| MBX Biosciences Inc. | Peter Kent Hawryluk | Director, President & CEO | 16 Sep 2024 | 1,396,762 | 0 | - | - | Series B Convertible Preferred Stock | ||
| MBX Biosciences Inc. | Peter Kent Hawryluk | Director, President & CEO | 16 Sep 2024 | 970,873 | 0 | - | - | Series C Convertible Preferred Stock | ||
| MBX Biosciences Inc. | Peter Kent Hawryluk | Director, President & CEO | 16 Sep 2024 | 345,705 | 0 | - | - | Series A Convertible Preferred Stock | ||
| MBX Biosciences Inc. | Peter Kent Hawryluk | Director, President & CEO | 16 Sep 2024 | 283,846 | 481,397 | - | - | Common Stock | ||
| MBX Biosciences Inc. | Peter Kent Hawryluk | Director, President & CEO | 16 Sep 2024 | 115,914 | 398,277 | - | - | Common Stock | ||
| MBX Biosciences Inc. | Peter Kent Hawryluk | Director, President & CEO | 16 Sep 2024 | 76,969 | 0 | - | - | Series B Convertible Preferred Stock | ||
| MBX Biosciences Inc. | Peter Kent Hawryluk | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 120,436 | 120,436 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges